期刊文献+

金黄色葡萄球菌对万古霉素敏感性试验方法评价 被引量:1

Evaluation of methods for detecting susceptibility of Staphylococcus aureus to Vancomycin
下载PDF
导出
摘要 目的比较不同方法检测金黄色葡萄球菌对万古霉素敏感性试验结果。方法将1株从临床标本中分离的异质性耐万古霉素的金黄色葡萄球菌(h-VRSA)在含有不同浓度的万古霉素培养基上连续转种诱导,得到一系列对万古霉素不同程度耐药的菌株,分别用琼脂筛选法、微量肉汤稀释法、E-test法、纸片扩散法和仪器法对万古霉素的敏感性进行检测。结果琼脂筛选法、微量肉汤稀释法和E-test法可以检测出金黄色葡萄球菌对万古霉素中介耐药(VISA),而纸片扩散法和仪器法则不能检出VISA。结论微量肉汤稀释法和E-test法是检测金黄色葡萄球菌对万古霉素敏感性可接受的方法。若以纸片扩散法和仪器法为常规药敏试验的实验室,应增加含6μg/ml的万古霉素脑心浸液琼脂进行筛查,以加强对VRSA和VISA的监测。 Objective To investigate the effective methods for detecting the susceptibility of Staphylococcus aureus to Vancomycin. Methotis An isolate of hoVRSA ( heterogeneous Vancomycin-resistant Staphylococcus aureus) isolated from clinical specimen was inoculatedon the increasing concentration of vancomycin agars. Varied degree of vancomycin of resistant S. aureus were obtained. The susceptibilities of these S. aureus to vancomycin were tested by agar screening test, broth microdilution method, E-test, disk diffusion method andautomated methods. Results Agar screening test, broth microdilution method and E-test are effective for detection of vancomycin-intermediate S. aureus VISA, but disk diffusion and automated methods could not detect VISA. Conclusion Broth microdilution method andE-test are acceptable methods for susceptibility testing of S. aureus to vancomycin. The laboratories using automated methods and diskdiffusion method as routine susceptibility test should consider adding a vancomycin agar screen plate to enhance detection of VRSA andVISA.
出处 《临床检验杂志》 CAS CSCD 北大核心 2006年第3期185-187,共3页 Chinese Journal of Clinical Laboratory Science
基金 安徽省高等学校省级自然科学研究项目(2006-KJ-379b)。
关键词 金黄色葡萄球菌 万古霉素 药物敏感性试验 Staphylococcus aureus vancomycin resistance methods
  • 相关文献

参考文献9

  • 1Clinical and laboratory Standard Institute/National Committee for Clinical laboratory Standards. Performance standards for antimicrobial susceptibility testing, fifteenth informational supplement[ S]. Document M100-S15. NCCLS. 2005.
  • 2马筱玲,王敬华,李华,陈多炎,濮跃晨.异质性万古霉素耐药葡萄球菌分离及生物学特性观察[J].中华微生物学和免疫学杂志,2004,24(7):583-586. 被引量:48
  • 3Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin[J]. Lancet, 1997,350(12) : 1670-1673.
  • 4Centers for disease control and prevention. Investigation and control of vancomycin-intermediate and resistant Staphylococcus aureus : A guide for health department and infection control personnel. 2004(Accessed at http://www.cdc.gov/ncidod/hip/ARESIST/visa_vrsa_guide.pdf)
  • 5Marlowe E M, Cohen M D, Hindler J F, et al. Practical strategies for detecting and confirming vancomycin-intermediate Staphylococcus aureus:a tertiary-care hospital laboratory's experience[ J ]. J Clin Microbiol, 2001,39 ( 7 ) :2637 -2639.
  • 6Cui L Z,Ma X X,Sato K,et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus [ J]. J Clin Microbiol,2003,41 ( 1 ) :5-14.
  • 7Cui L Z, Murakami H, Kuwahara-Arai K, et al. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50[J].Antimicrob Agents Chemother,2000,44(9) :2276-2285.
  • 8Ruef C. Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureu[J]. Infection,2004,32(6) :315-327.
  • 9Takayama Y, Hanaki H, Irinoda K, et al. Investigation of methicillin-resistant Staphylococcus aureus showing reduced vancomycin susceptibility isolated from a patient with infective endocarditis [ J ]. Int J Antimicrob Agent,2003,22(6) :567-573.

二级参考文献24

  • 1CDC. Staphylococcus aureus resistant to Vancomycin-United States,2002. Morb Mortal Wkly Rep, 2002, 51(26): 565-567.
  • 2CDC. Public Health Dispatch: Vancoomycin-Resistant Staphylococcus aureusPennsylvania, 2002. Morb Mortal Wkly Rep, 2, 2002, 51(40): 902.
  • 3Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother, 1997, 40(1): 135-136.
  • 4Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet, 1997, 350(12): 1670-1673.
  • 5Sieradzki K, Villari P, Tomasz A. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of Staphylococci. Antimicrob Agents Chemother, 1998, 42(1):100-107.
  • 6Marchese A, Balistreri G, Tonoli E, et al. Heterogeneous vancomycin resistance in mehthiillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital . J Clin Microbiol, 2000, 38(2): 866-869.
  • 7Poly MC, Grelaud C, Martin C, et al. First clinical isolate of vancomycin-intermediate Stsaphylococcus in a French hospital. Lancet, 1998,351: 1212.
  • 8Viedma DG, Rabadan PM, Diaz M, et al. Heterogeneous antimicrobial resistance patterns in polyclonal populations of coagulase-negative Staphylococcus isolated from catheters. J Clin Microbiol, 2000, 38(4): 1359-1363.
  • 9Wong SSY, Ho PL, Woo PCY, et al. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis, 1999,29: 760-767.
  • 10CDC. Investigation and Control of Vancomycin-Intermediate and resistant Staphylococcus aureus: A guide for health department and infection control personnel. Atlanta, GA. 2003 (Accessed at http://www. cdc.gov/ncidod/hip/ARESIST/visa-vrsa-guide. pdf)

共引文献47

同被引文献8

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部